NYSE$XRN
Global Medical REIT Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Announced first quarter 2022 financial results, invested $24 million in medical real estate during the quarter, and had an additional $53 million under contract.
Global Medical REIT reported a solid start to 2022 with stable results, acquiring $24 million in medical real estate at an average cap rate of 7.2%. Rental revenue increased 16.6% year-over-year to $31.9 million. Net income attributable to common stockholders totaled $2.7 million, or $0.04 per diluted share.
- Acquired $24 million in medical real estate during the first quarter at an average cap rate of 7.2%.
- Completed two acquisitions post-quarter end for $29.9 million at a weighted average cap rate of 6.5%.
- Rental revenue for the first quarter increased 16.6% year-over-year to $31.9 million.
- The company's portfolio was 97.0% occupied with an annualized base rent of $105.4 million as of March 31, 2022.
Headline financials
Revenue & EPS history
Global Medical REIT · Revenue · Quarterly
$31.9M
Forward guidance
The company remains confident in its prospects for the balance of the year, citing a strong portfolio and balance sheet.
Tailwinds
- Well-diversified portfolio producing stable results.
- Strong and stable cash flows from the portfolio.
- Ample capacity and liquidity to fund growth objectives.
- Completed acquisitions post-quarter end.
- Properties under contract for future acquisitions.
Headwinds
- Markets remain competitive for high-quality assets.
- Uncertainty is heightened amid inflationary pressures.
- Rising interest rates.
- Global issues.
- Acquisitions may not close on a timely basis or at all.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.1%
Avg return
30 days after
56%
22 / 39 earnings
Positive
+7.3%
Q4 2016
Best reaction
-9.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.2% | -4.2% | — | |
| Q4 2025 | -1.6% | -2.6% | -13.2% | |
| Q3 2025 | +1.8% | +3.2% | +1.7% | |
| Q1 2025 | -9.8% | -11.7% | -17.0% | |
| Q4 2024 | +3.8% | +4.4% | +3.1% | |
| Q3 2024 | -2.6% | -3.6% | -7.4% | |
| Q2 2024 | -1.8% | -0.3% | +1.0% | |
| Q1 2024 | +3.4% | +4.8% | +8.4% | |
| Q4 2023 | -5.6% | -2.7% | -5.7% | |
| Q3 2023 | -1.8% | -0.8% | +11.7% | |
| Q2 2023 | +3.5% | +4.8% | -1.5% | |
| Q1 2023 | +0.8% | +1.8% | +1.9% | |
| Q4 2022 | -4.0% | -1.2% | -13.0% | |
| Q3 2022 | -0.9% | +0.2% | +12.3% | |
| Q2 2022 | -0.5% | -1.3% | -11.0% | |
| Q1 2022 | -5.3% | -11.9% | -12.5% | |
| Q4 2021 | -3.2% | -2.2% | +1.9% | |
| Q3 2021 | +1.6% | +1.0% | -2.5% | |
| Q2 2021 | -0.7% | -0.2% | +3.7% | |
| Q1 2021 | -1.2% | +1.0% | +5.2% | |
| Q4 2020 | +1.6% | +3.9% | +0.2% | |
| Q3 2020 | +2.0% | +1.4% | +7.2% | |
| Q2 2020 | +4.8% | +11.4% | +11.6% | |
| Q1 2020 | +7.0% | +9.3% | +26.0% | |
| Q4 2019 | +4.7% | -7.2% | -41.1% | |
| Q3 2019 | +2.3% | +9.5% | +22.4% | |
| Q2 2019 | -0.7% | +1.8% | +5.0% | |
| Q1 2019 | +1.4% | +4.5% | +7.1% | |
| Q4 2018 | +0.8% | +2.6% | -2.0% | |
| Q3 2018 | +2.2% | +2.0% | +6.4% | |
| Q2 2018 | +4.3% | +6.7% | +12.2% | |
| Q1 2018 | +2.6% | -0.1% | +4.6% | |
| Q4 2017 | +5.8% | +6.3% | +3.9% | |
| Q3 2017 | +3.1% | +3.7% | -2.8% | |
| Q2 2017 | +0.7% | +2.8% | +2.8% | |
| Q1 2017 | -1.2% | +0.0% | +0.3% | |
| Q4 2016 | +7.3% | +9.3% | +17.1% | |
| Q3 2016 | -8.5% | -14.9% | -0.2% | |
| Q2 2016 | +1.1% | +2.3% | -5.0% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro